Ensysce Biosciences Inc (ENSC)vsRoyalty Pharma Plc (RPRX)
ENSC
Ensysce Biosciences Inc
$0.27
-2.56%
HEALTHCARE · Cap: $4.56M
RPRX
Royalty Pharma Plc
$56.43
-2.64%
HEALTHCARE · Cap: $32.78B
Smart Verdict
WallStSmart Research — data-driven comparison
Royalty Pharma Plc generates 51739% more annual revenue ($2.44B vs $4.71M). RPRX leads profitability with a 33.9% profit margin vs -250.4%. RPRX earns a higher WallStSmart Score of 65/100 (C+).
ENSC
Avoid31
out of 100
Grade: F
RPRX
Buy65
out of 100
Grade: C+
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+59.5%
Fair Value
$1.01
Current Price
$0.27
$0.74 discount
Margin of Safety
-64.1%
Fair Value
$34.68
Current Price
$56.43
$21.75 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Keeps 34 of every $100 in revenue as profit
Strong operational efficiency at 100.3%
Earnings expanding 23.2% YoY
Areas to Watch
0.0% earnings growth
Smaller company, higher risk/reward
Weak financial health signals
ROE of -1149.0% — below average capital efficiency
Expensive relative to growth rate
Moderate valuation
Elevated debt levels
Weak financial health signals
Comparative Analysis Report
WallStSmart ResearchBull Case : ENSC
The strongest argument for ENSC centers on Debt/Equity.
Bull Case : RPRX
The strongest argument for RPRX centers on Profit Margin, Operating Margin, EPS Growth. Profitability is solid with margins at 33.9% and operating margin at 100.3%. Revenue growth of 11.0% demonstrates continued momentum.
Bear Case : ENSC
The primary concerns for ENSC are EPS Growth, Market Cap, Piotroski F-Score.
Bear Case : RPRX
The primary concerns for RPRX are PEG Ratio, P/E Ratio, Debt/Equity.
Key Dynamics to Monitor
ENSC profiles as a turnaround stock while RPRX is a mature play — different risk/reward profiles.
ENSC carries more volatility with a beta of 0.82 — expect wider price swings.
RPRX is growing revenue faster at 11.0% — sustainability is the question.
RPRX generates stronger free cash flow (761M), providing more financial flexibility.
Bottom Line
RPRX scores higher overall (65/100 vs 31/100), backed by strong 33.9% margins and 11.0% revenue growth. ENSC offers better value entry with a 59.5% margin of safety. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Ensysce Biosciences Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Ensysce Biosciences, Inc., a clinical-stage biotechnology company, is dedicated to the development of various prescription drugs. The company is headquartered in La Jolla, California.
Royalty Pharma Plc
HEALTHCARE · BIOTECHNOLOGY · USA
Royalty Pharma plc is a buyer of biopharmaceutical royalties and funder of innovations in the biopharmaceutical industry in the United States. The company is headquartered in New York, New York.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?